Local News

• Abbott completes acquisition of Ibis Biosciences, a subsidiary of Isis  Isis Pharmaceuticals and Abbott announced that Abbott has completed its purchase of Ibis Biosciences, an Isis subsidiary, for a closing purchase price of $175 million.
  Isis Pharmaceuticals, Inc. January 06, 2009  
• Boston Scientific acquires Labcoat Limited  Boston Scientific announced that it has acquired Labcoat Limited, a privately held, development-stage drug-eluting stent technology company located in Galway, Ireland. Terms of the acquisition were not disclosed.
  Boston Scientific Corporation January 06, 2009  
• First NxStage home hemodialysis patients celebrate five-year anniversary  NxStage Medical announced that a group of its first patients are celebrating their five-year anniversary of home hemodialysis treatment with the NxStage(R) System One(TM), the first truly portable home hemodialysis machine.
  NxStage Medical, Inc. January 06, 2009  
• ARIAD expands management team with executive appointments  ARIAD Pharmaceuticals announced the appointment of 3 senior executives to ARIAD's management team in newly created positions: Daniel M. Bollag, Ph.D. as senior VP, regulatory affairs and quality, Andreas Woppmann, Ph.D. as VP, manufacturing operations and Kelly M. Schmitz as VP, IT and operations.
  ARIAD Pharmaceuticals, Inc. January 06, 2009  
• MedImmune submits Marketing Authorisation Application in EU for intranasal flu vaccine  MedImmune, the global biologics unit of AstraZeneca, announced that it has submitted a Marketing Authorisation Application (MAA) for its nasal spray live attenuated influenza vaccine (LAIV), which is now being reviewed by the European Medicines Agency (EMEA).
  AstraZeneca January 06, 2009  
• Endo Pharmaceuticals to acquire Indevus Pharmaceuticals  Endo Pharmaceuticals and Indevus Pharmaceuticals announced that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash.
  Endo Pharmaceuticals January 05, 2009  
• Dick Bond leaving Tyson Foods  Dick Bond, president and chief executive officer of Tyson Foods, announced he is leaving the company, effective immediately. Leland Tollett, former chairman and CEO of the company, has agreed to return to the company as President and CEO on an interim basis.
  Tyson Foods, Inc. January 05, 2009  
• PPD enters into strategic collaboration with Merck  PPD announced it has entered into a strategic collaboration with Merck & Co. involving vaccine testing and assay development. Under the agreements, PPD purchased Merck's 130,000 square-foot vaccine testing laboratory and related equipment in Wayne, Penn.
  PPD, Inc. January 05, 2009  
• Cubist Pharmaceuticals, the developer of CUBICIN, announces submission of 2 INDs  Cubist Pharmaceuticals announced that the company submitted two Investigational New Drug Applications (INDs) with the U.S. Food and Drug Administration (FDA) on December 23rd.
  Cubist Pharmaceuticals, Inc. January 05, 2009  
• Bruker Daltonics and Queensland Institute of Medical Research expand collaboration  Bruker Daltonics and the Queensland Institute of Medical Research (QIMR) announced the installation of the first maXis(TM) Ultra-High Resolution Time-Of-Flight (UHR-TOF) mass spectrometer in Australasia, thereby further strengthening the collaboration between Bruker and QIMR.
  Bruker Corporation January 05, 2009  

   (next 10 articles)